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Although chromosomal instability (CIN) is a common phenomenon in cleavage-stage 31 
embryogenesis following in vitro fertilization (IVF)1-3, its rate in naturally conceived human 32 
embryos is unknown. CIN leads to mosaic embryos that contain a combination of 33 
genetically normal and abnormal cells and is significantly higher in in vitro produced 34 
preimplantation embryos as compared to in vivo-conceived preimplantation embryos4. 35 
Even though embryos with CIN-derived complex aneuploidies may arrest between the 36 
cleavage- and blastocyst-stage of embryogenesis5,6, a high number of embryos containing 37 
abnormal cells can pass this strong selection barrier7,8. However, prevalence and extent of 38 
CIN during prenatal development and at birth, following IVF treatment, is not well 39 
understood. Here we profiled the genomic landscape of fetal and placental tissues 40 
postpartum from IVF and naturally conceived children to investigate the prevalence and 41 
persistence of large genetic aberrations that have likely arisen from IVF-related CIN. We 42 
demonstrate that CIN is not preserved at later stages of prenatal development, and that de 43 
novo numerical aberrations or large structural DNA imbalances occur at similar rates in 44 
IVF and naturally conceived live-born neonates. Our findings affirm that human IVF 45 
treatment has no detrimental effect on the chromosomal constitution of fetal and placental 46 
lineages. 47 
 48 
CIN is a common event in human cleavage-stage embryogenesis that results in a high frequency 49 
of chromosomal mosaicism in IVF embryos1-3 and likely provides an explanation for the low 50 
success rate per embryo transfer of IVF9. Strikingly, most IVF embryos are mixtures of euploid 51 
and aneuploid cells and only a low fraction of IVF embryos contain a normal karyotype in all 52 
blastomeres1,10. Between the cleavage- and blastocyst-stage of embryogenesis, CIN may cause 53 
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complex aneuploidies and the arrest of many embryos5,6. Even after this substantial selection, 54 
genetically aberrant cells can be preserved at high frequency in the developing blastocysts, such 55 
that about 40% of blastocysts have been reported to be uniformly euploid7,8. Despite the high 56 
prevalence of human IVF embryos with aberrant chromosomal configurations, its clinical 57 
implications are poorly understood. Recently, we established Bos taurus as a model organism to 58 
study CIN at cleavage stage embryogenesis11 and showed that CIN in in vitro-produced embryos 59 
is significantly higher in prevalence when compared to in vivo-conceived embryos4, rising the 60 
alarming concern about the suboptimal in vitro environment on genetic integrity of embryos. 61 
However, the fate of aberrant cells after cleavage-stage embryogenesis is not clear and it remains 62 
impossible to investigate naturally conceived human embryos in vivo. 63 
 Cell lineages containing genetic aberrations in mosaic cleavage-stage embryos have been 64 
speculated to survive in the trophectoderm, having no or little influence on the composition of 65 
the inner cell mass and its subsequent fetal development12. This possibility is in accordance with 66 
the confined placental mosaicism found in approximately 1–2% of ongoing natural pregnancies13 67 
and the low prevalence of genetic mosaicism in postnatal and adult DNA samples14. 68 
Furthermore, euploid blastomeres may outgrow blastomeres with chromosomal aberrations15, 69 
allowing normal embryonic development and birth. This view of preferential selection of normal 70 
cells is supported by recent studies reporting the birth of healthy babies after intrauterine transfer 71 
of genetically mosaic IVF embryos16,17. In addition, a recent report described lineage-specific 72 
fate in chimeric mouse embryos. This report demonstrated that different mechanisms act on 73 
aneuploid cells in fetal or placenta lineages, such that apoptotic depletion of aneuploid cells 74 
occurs in fetal lineage, whereas aneuploid cells in placenta persist but slow down their 75 
divisions18.  76 
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 To investigate the persistence of IVF-related CIN, we profiled de novo DNA copy 77 
number alterations in DNA samples extracted from cord blood cells and placental tissue, which 78 
are derived from embryonic and extra-embryonic cell lineages, respectively, of both IVF and 79 
naturally conceived neonates using haplarithmisis3 and molecular karyotyping. Importantly, the 80 
transferred embryos of IVF newborns were not screened nor counter selected for chromosomal 81 
aneuploidy status before intrauterine transfer. Following live birth, we scrutinized genome-wide 82 
single nucleotide polymorphism (SNP) profiles in DNA from the father, mother, placenta and 83 
neonate umbilical cord blood of 111 families (quartets; Fig. 1a), of which 49 and 62 quartets 84 
were from IVF and natural pregnancies, respectively. In the IVF cohort, the infertile patients 85 
underwent fresh or frozen IVF (n = 32) or intracytoplasmic sperm injection (ICSI, n = 17) 86 
embryo transfer, with about 4 out of 5 embryos transferred on days 2/3 (n=38, 77.5%) and the 87 
remaining on days 5/6 at blastocyst stage (n=11, 22.5%). These quartets were further subdivided 88 
based on birthweight at delivery, with 48 IVF and 50 natural conception families categorized as 89 
‘appropriate for gestational age’ (AGA), and one IVF and 12 natural conception families as 90 
‘small for gestational age’ (SGA) (Supplementary Tables 1 and 2). DNA copy number variants 91 
(CNVs) were classified by whether they were found exclusively in a single sample or a few to all 92 
samples within a quartet. This approach empowered our analysis and allowed us to differentiate 93 
inherited CNVs (present in either or both parents, umbilical cord blood and placenta), de novo 94 
CNVs (present in placenta and umbilical cord blood only) and placental de novo CNVs (present 95 
in placenta only). CNVs were detected by the combined use of logR values, B Allele Frequency 96 
(BAF) and parent-of-origin haplotypes (haplarithms). The latter analysis allowed us to account 97 
for maternal DNA contribution in placental tissue (Fig. 1b, Extended Data Fig. 1), to identify 98 
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the parental origin of de novo CNVs (Fig. 1c and Table 1) and to more accurately estimate the 99 
level of mosaicism of CNVs within the DNA sample (Fig. 2a, b and Table 1).  100 
We detected de novo large CNVs (>100 kb) in placental genomes of twelve families; of 101 
the total fifteen detected aberrations four were also present in newborns and eleven were 102 
exclusively present in the placenta. We did not detect any CNVs present only in umbilical cord 103 
blood DNA, which would indicate a genomic alteration in the neonate only. The mosaic (n = 12) 104 
de novo CNVs were 5–70% mosaic (Table 1) and were together with de novo non-mosaic CNVs 105 
(n = 3) randomly located across the genome (Fig. 1d). Our analysis showed comparable 106 
prevalence (P = 0.327 odds ratio test or P = 0.775 Pearson’s chi square test) of de novo CNVs in 107 
both cohorts with AGA: six of the 50 families with naturally conceived neonates (12.0%) and in 108 
three of the 48 families with IVF neonates (6.3%) (Table 1). When IVF with fresh and frozen 109 
embryo transfers was compared to ICSI fresh/frozen embryo transfers similar proportions of 110 
mosaic de novo CNV cases were found (6.3%, 2/32 and 5.9%, 1/17, respectively, P = 0.96 odds 111 
ratio test), indicating that the mode of fertilization (IVF vs ICSI) and embryo freezing are 112 
unlikely to influence the rate of large CNVs in fetal and placental lineages. 113 
We found three partial trisomies with different levels of mosaicism in family P172 from 114 
the naturally conceived cohort and a mosaic full-chromosome trisomy in family P106 from the 115 
IVF cohort (Fig. 2a, b, Table 1 and Extended Data Figs. 2 and 3), showing mosaicism of 5–116 
25%. We obtained biopsies from two other spatially distinct locations, applied haplarithmisis and 117 
confirmed the results using droplet digital PCR (ddPCR) (Fig. 2c and Supplementary Table 3). 118 
The partial mosaic trisomies on Chr 6 (22.4 Mb), Chr 9 (5.8 Mb) and Chr 21 (22.0 Mb) of P172 119 
were not present in the other placental biopsies (Fig. 2c and Extended Data Fig. 2). In contrast, 120 
the full Chr 2 mosaic trisomy was present in all the P106 placental biopsies (Fig. 2c and 121 
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Extended Data Fig. 3). This result indicates that the mosaic Chr 2 trisomy arose as CIN in the 122 
early cleavage-stage embryo, but segregated into the placental lineage only (Fig. 3 and Table 1), 123 
because it was present across different parts of the placenta with the same degree of mosaicism. 124 
The presence of the low-degree mosaic Chr 2 trisomy reinforces an earlier observation in mouse 125 
embryos, which suggested a progressive reduction of aneuploid cell lineage in placenta18 because 126 
only 10% of the cells carried the anomaly. However, the segmental trisomies in family P172 127 
were present in only one of the placental locations, indicating that these genomic alterations 128 
either emerged later in gestation through local clonal expansion of aberrant cells in the placenta 129 
or appeared early in development, contributed to the trophectoderm and were largely overgrown 130 
by normal cells in placental tissue. The presence of multiple de novo DNA copy number variants 131 
has recently been shown to lead to genomic disorders19. The finding that multiple CNVs are 132 
present with a different degree of mosaicism, albeit in placenta genome only, is indicative that 133 
they occurred in a cumulative fashion20. 134 
To further investigate CNV heterogeneity across the placenta and reaffirm the (non-) 135 
mosaic nature of the detected de novo CNVs, we further analysed 20 DNA samples derived from 136 
spatially different locations of all but two placentas (F351 and F1021) with de novo CNVs 137 
(Table 1). As expected, de novo non-mosaic CNVs found in both placenta and cord blood were 138 
consistently present in all the biopsies, whereas de novo mosaic CNVs were not present in the 139 
other biopsies (Extended Data Fig. 4). Importantly, the full Chr 2 mosaic trisomy was found in 140 
all the biopsies (Extended Data Fig. 3), indicating its early embryonic origin (see above). 141 
We identified two clinically significant non-mosaic CNVs in the SGA cohort, with the 142 
genetic aberrations found both in umbilical cord and placental DNA. P153 carried a de novo 143 
deletion on Chr 7q11.23. Postpartum follow-up revealed clinical features of Williams–Beuren 144 
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syndrome21. P177 carried a paternally inherited duplication on Chr 15 with features of Chr 145 
15q13.3 duplication syndrome22,23. The low birth weight of these neonates might be indicative of 146 
the underlying chromosomal aberration; therefore, the SGA neonates should be subjected to 147 
submicroscopic chromosomal analysis.  148 
Although the prevalence of de novo CNVs in SGA (25.0%, 3/12) and AGA (12.0%, 6/50) 149 
groups of the cohort of natural conceptions is not significantly different (P = 0.44, odds ratio 150 
test), current sample size for SGA (n = 12), provides limited statistical power (<0.50). A study 151 
with increased SGA sample size (n > 44, Methods) is required to evaluate the effect of 152 
birthweight on the prevalence of de novo CNVs. Furthermore, our data indicates that the current 153 
sample size (n=50 per AGA cohort) provides limited statistical power to detect CNVs with small 154 
effect size (w=0.1-0.2) between the two cohorts. We estimated that future studies with smaller 155 
effect size require a data set of ~10-fold larger24. 156 
The human placenta is characterized by deep invasion of trophoblasts into the 157 
endometrium. Trophoblasts have similar properties to cancer cells, including rapid proliferation, 158 
migration and invasiveness. As CIN is a hallmark of both tumorigenesis and early 159 
embryogenesis, a recent study hypothesized that the placenta resembles tumor tissue by 160 
demonstrating an extensive load of de novo genomic gains, harboring excessively expressed 161 
genes required for the invasiveness of trophoblasts25. Our results challenge this view; as we 162 
found that placental de novo CNVs were present in only 12 of the 111 families (10.8%) (Fig. 1d 163 
and Table 1), and placental heterogeneity was found in 85.7% (6/7) of the studied ‘placenta 164 
only’ de novo mosaic CNVs. To determine whether genes located in the de novo CNV regions (n 165 
= 475) had specific placental biology-related functions, we analyzed gene expression in full-term 166 
placentas following live birth (Methods). Only 18.1% (n = 86) of these genes had moderate or 167 
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high expression according to the whole RNA sequencing of placental tissue (Fig. 2d and 168 
Supplementary Table 4), and genes from regions with de novo gains (18.0%, 77/428) and 169 
losses (19.1%, 9/47, P = 0.84 odds ratio test) demonstrated similar proportion of moderate-to-170 
high expression genes in placental tissue. Moreover, enrichment analyses of genes located in de 171 
novo CNV regions did not reveal any molecular pathway related to placental biology. All this 172 
indicates that these new CNVs are likely sporadic and do not play any role in placental biology.  173 
In this study, our main outcome measure was the extent and prevalence of de novo large 174 
CNVs (>100 kb) in live-born IVF-conceived neonates when compared to naturally conceived 175 
ones. Although we have not studied the embryonic loss with or without aneuploidies in IVF- or 176 
naturally conceived pregnancies, we speculate that when all cells of day-3 (cleavage-stage) 177 
embryos are investigated for the presence of (segmental) aneuploidies, on average 80% of the 178 
embryos present with at least one aneuploid cell (range 70%-90%)1,3,10. The IVF success rate per 179 
embryo transfer of day-3 embryos is about 35% in Helsinki and Tartu IVF centres. Assuming 180 
that all euploid day-3 embryos survive, they would constitute at most 20% of the total number of 181 
embryos transferred resulting in pregnancy/delivery, but indicating that at least 15% of all 182 
embryos did contain some aneuploid cells. This would amount to 60% and 40% of the live births 183 
resulting from respectively euploid and mosaic euploid/aneuploid cleavage-stage embryos. 184 
Conversely, about 20% (15/80%) of mosaic embryos survive and result in healthy live births, 185 
whereas 80% (65/80%) are selected against. Since it is unlikely that all euploid embryos make it 186 
to term, the latter is a lower estimate.  187 
Mosaicism rates in human IVF embryos are still debated and vary across studies 188 
primarily because of the definition of mosaicism used, the technology applied, and the variance 189 
in assisted reproduction protocols used. First, important differences in the definition of a mosaic 190 
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embryo exist between studies. Embryos having both euploid and aneuploid cells were defined as 191 
mosaic in 199326, but since, an arbitrary classification of embryos as mosaic or diploid 192 
influenced the mosaicism rate reported by different studies. For instance, some studies27-29 193 
considered an embryo mosaic only if more than 50% of blastomeres within the embryo were 194 
aneuploid. The reason for considering an embryo having less than 50% abnormal cells as diploid 195 
was that they are likely viable and a low percentage of abnormal cells in those embryos was 196 
believed clinically irrelevant. Second, since the discovery of aneuploidies in human 197 
preimplantation embryos30,31, different technologies have been used to profile the chromosomal 198 
constitution of preimplantation embryos. Depending on the technology used the rate of 199 
mosaicism was reported to range from 15%32 to >90%1,3. However, in a meta-analysis of all 200 
technologies included and carried out on 815 embryos from different developmental stages, 73% 201 
were classified as mosaic10. The high variability occurs, because different technologies have 202 
different sensitivities and specificities for profiling the ploidy state of a selected chromosomes 203 
(e.g. FISH32) or the entire genome (microarray1,3 or next-generation sequencing3,33). The above, 204 
and the number of cells per embryo analyzed with those technologies, can affect the reported 205 
embryo mosaicism rates in those studies, with the studies analysing all the cells from a single 206 
embryo showing the higher rate of mosaicism10. In current study, we applied the same wet- and 207 
dry-lab technologies as in our preimplantation embryo studies3,34,35 and further validated our 208 
approach using sensitive droplet digital PCR and standard copy number analysis methods36,37, 209 
allowing us to rule out technology-driven bias. Third, the mosaicism rate is reported to be 210 
influenced by the fertility clinic where the IVF procedure is carried out38; one key component 211 
that can explain differences in the reported mosaicism rate is embryo culture conditions39. 212 
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However, in this study, the IVF procedure, including culture conditions, were similar in the 213 
participating IVF clinics.  214 
 Taken together, our findings suggest that the high level of chromosomal mosaicism in 215 
IVF cleavage-stage embryos is not preserved at later stages of prenatal development. Although 216 
we found a low-level mosaic trisomy in one IVF placental genome, it was not present in the fetal 217 
lineage of the same pregnancy, suggesting a proliferative defect of trisomic cells. The sporadic 218 
de novo genomic aberrations found in approximately 10.8% of pregnancies were scattered across 219 
the genome and represented random and rare events of embryonic CIN, without any observed 220 
functional consequence on placental biology or fetal health. Thus, our findings confirm that the 221 
IVF procedure has no detrimental effect on large genomic rearrangements in fetal and placental 222 
lineages of live-born neonates, which helps to remove a major health concern for IVF neonates.  223 
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Figure Note 344 
Figure legends 345 
Figure 1 | Haplarithmisis reveals genetic mosaicism with parent-of-origin information. (a) 346 
Schematic representation of a quartet. (b) Haplarithmisis can determine the maternal DNA 347 
contribution to the bulk placental DNA sample (see Methods). (c) A maternally inherited CNV 348 
(red arrows) and placental de novo CNV with paternal origin found on Chr 5 of P070 (purple 349 
arrow). B allele fraction (BAF) of a SNP is the signal intensity of allele B over signal intensities 350 
of both expected alleles for that SNP (𝐵𝐴𝐹 = ( &'(&)), and logR (relative copy number) of that 351 
SNP is the base 2 logarithm of the summed normalized signal intensities of both alleles over 352 
expected signal intensity values (𝑙𝑜𝑔𝑅 = ./01234.45245647). (d) Overview of de novo CNVs found in this 353 
study (see also Source data). G and L denote gains and losses, respectively, as shown in Table 354 
1.  355 
 356 
Figure 2 | Mosaic de novo CNVs and overlap with placental transcriptome. Haplarithms 357 
revealed de novo mosaic (a) partial trisomies in P172 placenta of paternal origin (see also 358 
Extended Data Fig. 2) and (b) full-chromosome trisomy in P106 placenta of maternal origin 359 
(see also Extended Data Fig. 3). These aberrations are indicated by purple arrows. (c) 360 
Validation of detected mosaic de novo CNVs by ddPCR (each circle and error bar indicate mean 361 
and standard deviation, respectively, of four independent measurements). (d) Placental 362 
expression of genes detected in de novo CNV regions, expressed as reads per kilobase per 363 
million mapped reads (RPKM). 364 
 365 
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Figure 3 | Schematic representation of plausible occurrence and segregation of de novo 366 
CNVs into fetal or placental lineages found in this study. De novo CNVs can occur before 367 
conception in the germ cells or during conception (I), during the cleavage divisions of early 368 
development (II-IV) or later during development, e.g. blastocyst-stage embryogenesis (V-VI). 369 
Note that, for simplicity in the CIN-derived mosaic CNVs, we merely showed CNV burst in 2-370 
cell stage embryos (II-IV types) and blastocyst-stage embryos (V-VI types) (see also Table 1). 371 
Red circles indicate cells carrying de novo CNV.  372 
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Table 1 | De novo CNVs detected by haplarithmisis. 373 
 374 
a O:T demonstrates occurrence and type. Occurrence can be B = de novo copy number alteration occurred in both placenta and 375 
umbilical cord DNA samples, OP = de novo copy number alteration occurred in placental DNA sample only; and type can be in 376 
one of the stratified CNV types illustrated in Fig. 3. b CN = copy number; L = Loss; G = Gain; c parent of origin is determined 377 
based on the parental allele which is affected, e.g. maternal loss or gain means that maternal allele is deleted or duplicated, 378 
respectively;  for non-mosaic deletions present in both placenta and cord blood, we used parent-of-origin module of siCHILD to 379 
determine parental origin; d percentage of abnormal cells; e cnv:bps demonstrates number of CNVs (‘cnv’) found in spatially 380 
different placenta biopsies (‘bps’; see also Extended Data Figs. 2, 3 and 4); f more biopsies from these placentas were not 381 
available. 382 
Cohort Family Genome coordinates Length (bp) SNP-probes (#) O:T
a CNb Originc Mosaicism (%)d 
Biopsy 
(cnv:bps)e 
Naturally conceived.  
Appropriate birth weight 
for gestational age 
P017  Chr16:78670954-78867839  196885  37  OP:III/V  L1  Maternal  65%  1:3 
P073 Chr7:13238496-13348832 110336 26 OP:III/V L2 Paternal 60% 1:3 
P080 Chr3:174684649-174831994 147345 32 OP:III/V L3 Maternal 60% 1:3 
P142 Chr14:47624206-47746980 122774 16 OP:III/V L4 Paternal 70% 1:3 
P162 Chr14:64554517-64953726 399209 189 OP:III/V L5 Paternal 40% 1:3 
F351  Chr22:23250737-23644794  394057  99  B:I  L6  Maternal  -  NAf 
F351  Chr4:91709484-91910883  201399  24  OP:III/V   L7  Maternal  70%  NAf 
Naturally conceived.  
Small birth weight for 
gestational age 
P070 Chr5:103670162-104157752 487590 45 OP:III/V G1 Paternal 65% 1:3 
P153 Chr7:72305671-74115258 1809587 359 B:I L8 Maternal - 3:3 
P172 Chr21:26058246-48084247 22026001 5796 OP:III/V G2 Paternal 25% 1:5 
P172 Chr6:204072-22569968 22365896 4106 OP:III/V G3 Paternal 10% 1:5 
P172 Chr9:135277529-141031439 5753910 2915 OP:III/V G4 Paternal 5% 1:5 
IVF.  
Appropriate birth 
weight for gestational 
age 
P091 Chr16:21605180-21966869 361689 41 B:I L9 Maternal - 3:3 
P106 Chr2:1-243048760 243015748 44591 OP:III/V G5 Maternal 10% 5:5 
F1021 Chr17:2832092-3070476 238384 71 B:II G6 Maternal 40% NAf 
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METHODS 383 
 384 
Ethical approval. The study was approved by the local Ethics Committee of the University of 385 
Tartu (213/T-21) and the Ethics Committee of Helsinki University Central Hospital 386 
(285/13/03/03/2013). All couples signed the informed consent form.  387 
 388 
Selection of participating families. In total, 111 couples participated in this study 389 
(Supplementary Table 1 and 2), including 62 couples who delivered neonates after spontaneous 390 
conception (natural cohort) and 49 couples who delivered after IVF (IVF cohort). No prior 391 
genetic predisposition was identified in any of the couples participating in this study. Clinical 392 
data and biological material were collected from singleton pregnancies at birth from vaginal 393 
delivery or caesarean section (Supplementary Table 2). For each family, we isolated DNA from 394 
the father, mother, as well as the placenta and neonate umbilical cord blood following live birth 395 
(quartet DNA sample set). The natural cohort was divided into two subgroups based on the 396 
neonate birthweight: (i) AGA neonates, with a birthweight between the 10th and 90th percentile 397 
(n = 50 families), and (ii) SGA neonates, with a birthweight below the 10th percentile (n = 12 398 
families). The IVF cohort consisted of 48 families with AGA neonates and one family with an 399 
SGA neonate. Birthweight percentiles were calculated by using data from the Estonian Medical 400 
Birth Registry40 and the Finnish National Institute for Health and Welfare41.  401 
 402 
Sample collection and DNA extraction. Full-thickness placental blocks of around 1 cm were 403 
taken from placenta and stored at -80 °C for subsequent DNA extraction. To investigate placenta 404 
CNV heterogeneity, we analysed 3-5 biopsies from spatially distinct locations of 10 placentas 405 
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(Table 1 and Extended Data Figs. 2, 3 and 4). All samples were collected by the same medical 406 
personnel. Maturity and health of term placenta were confirmed by histological examination. A 407 
total of 9 mL of peripheral venous blood from parents and 4 mL of umbilical cord blood were 408 
collected into ethylenediaminetetraacetic acid-containing tubes (BD Vacutainer, Becton, 409 
Dickinson and Co.). In Estonia, DNA was isolated from blood and placental tissue by using the 410 
PureLink Genomic DNA Kit (Invitrogen, Life Technologies). DNA samples were eluted with 411 
200 µL of PureLink Genomic Elution Buffer (10 mM Tris-HCl, pH 9.0, 0.1 mM EDTA) and 412 
stored at -20 °C until analysis. Finnish parental DNA from blood samples was extracted by 413 
NucleoSpin Blood XL Kit (Macherey-Nagel) and DNA from umbilical cord blood by 414 
NucleoSpin Tissue Kit (Macherey-Nagel). NanoDrop 2000 (Thermo Fisher Scientific Inc.) was 415 
used to assess DNA concentration and purity. 416 
 417 
SNP genotyping. For SNP genotyping, the Infinium PsychArray-24 v1.1 (Illumina; GEO: 418 
GPL22819) and PsychArray-24 v1.3 BeadChip SNP arrays (Illumina; GEO: GPL26750) were 419 
used, which contains approximately 590,000 SNP markers with a median marker spacing of 5.5 420 
kb. Genotype calls, SNP B-allele frequency values and logR values of all samples were 421 
computed by the Illumina GenomeStudio software. 422 
 423 
Haplarithmisis. We applied haplarithmisis3 on each quartet DNA sample. Discrete SNP calls 424 
derived from umbilical cord blood were used as seeds to phase the parental genotypes. Parental 425 
haplarithms were used to infer DNA copy number state, parent-of-origin and level of mosaicism 426 
of de novo copy number alterations in placental/newborn’s DNA. Level of mosaicism was 427 
calculated as described42.  428 
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Haplarithmisis can be used to estimate contributions of maternal and fetal genomes in 429 
placental DNA samples. We carried out a simulation analysis by blending maternal and fetal 430 
alleles with different proportions (from 1%Mother : 99%Child to 99%Mother : 1%Child) and applied 431 
haplarithmisis (Extended Data Fig. 5). This process allowed us to determine accurately the 432 
maternal and fetal contributions to placental tissue (Supplementary Table 5 and Extended 433 
Data Fig. 1).   434 
 435 
Copy number profiling. We applied both PennCNV36 (with 0.2% false positive rate and 86% 436 
sensitivity for constitutional CNVs) and QuantiSNP37 (with 0.1% false positive rate for 437 
constitutional CNVs) algorithms as well as the copy number module of siCHILD3 on the raw 438 
logR values with minor modifications. Raw logR-values were smoothed by using a moving 439 
average window of five consecutive SNP probes, wave-corrected for GC% bias by a Lowess fit 440 
and normalized to a trimmed mean of normal diploid chromosomes. Normalized logR-values 441 
were segmented by piecewise-constant fitting43 (gamma = 14). A copy number alteration was 442 
considered reliable if more than six consecutive SNP probes supported the copy number change, 443 
its length was more than 33 kb (six times 5.5 kb median distance between two probes) and it was 444 
supported by raw or segmented parent-of-origin specific haplotypes, coined haplarithms. As a 445 
sanity check, we investigated whether there are signals that are detected only by haplarithmisis 446 
(Supplementary Table 6) or logR analysis (Supplementary Table 7). We did not include those 447 
in the analysis. 448 
Copy number analysis was empowered by our quartet sample-set and haplarithmisis, as 449 
we used all of the samples within a quartet to call a reliable genomic change. For each of the 450 
detected DNA copy number alterations in one sample (e.g. placenta), we checked whether the 451 
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same alteration was present in other samples of the same quartet. This approach allowed us to 452 
determine the parental origin of inherited CNVs, to detect de novo CNVs (i.e. in placental 453 
samples or in both placental and umbilical cord samples), to find CNVs exclusive to any of the 454 
samples (e.g. present solely in the placental genome) and to reveal genotyping artifacts. 455 
 456 
Other statistical and computational analysis. Since both predictor (with or without IVF 457 
treatment) and outcome (with or without de novo CNVs) are dichotomous, chi-squared test is the 458 
most suitable test44. To determine appropriate sample size, we performed a power analysis using 459 
chi-squared test with confidence level of at least 95% and feeding the conventional effect size 460 
(w) values of 0.1, 0.3 and 0.5, which correspond to small, medium and large effect sizes, 461 
respectively45. With a medium effect size at least 40 samples per cohort is required to reach to 462 
the power of 0.824. Given the sample size of about 50 per cohort (50 naturally conceived quartets 463 
and 48 IVF quartets with appropriate birthweight for gestational age), this study has >80% power 464 
(alpha = 0.05; middle effect size of 0.3; case to control ratio ca 1) to detect a significant 465 
difference (<0.05).  466 
We also compared large CNVs with mosaic or non-mosaic nature separately. The rate of 467 
mosaic large CNVs found in naturally conceived versus IVF-conceived AGA groups were not 468 
significantly different (P = 0.157 Pearson’s chi square test). Similarly, the rate of non-mosaic 469 
CNVs found in naturally conceived versus IVF-conceived AGA groups were not significantly 470 
different (P = 0.977 Pearson’s chi square test). 471 
We applied Hotelling’s T-square multivariate statistical test on the numerical 472 
demographic features of AGA neonates of both IVF and natural cohorts, including birth weight, 473 
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birth length, placenta weight, parity and gestational age. This analysis showed no significant 474 
difference in these cohorts (P = 0.22, Hotelling’s two sample T2-test). 475 
For statistical analyses we applied R (http://www.r-project.org/). For visualization 476 
purposes we applied siCHILD3 and R (http://www.r-project.org/). 477 
 478 
RNA sequencing and comparison with placental transcriptome. We performed RNA 479 
sequencing as described previously46 (Supplementary Table 4). Briefly, 12 placental samples 480 
were collected from singleton pregnancies at term (range, 38–42 weeks of gestational age). 481 
Placental samples from different families were used for RNA sequencing and CNV analysis. 482 
Full-thickness placental blocks of around 2–3 cm were taken from three different regions of 483 
placenta. Total RNA was extracted with the mirVana miRNA Isolation Kit (Ambion, Life 484 
Technologies), and RNA samples were pooled. DNA contamination was removed with the 485 
DNA-free Kit (Invitrogen, Life Technologies). Agilent 2100 Bioanalyzer and RNA 6000 Nano 486 
Kit (Agilent Technologies) were used to assess the integrity and concentration of total RNA 487 
samples.  488 
For RNA-Seq library preparation, 45 ng of total RNA was amplified with the Ovation 489 
RNA-Seq System V2 Kit (NuGen). The SOLiD 5500 System DNA fragment library (Life 490 
Technologies) was used for library preparation. Pooled samples were analyzed on three 491 
FlowChip lanes, and approximately 40 million mappable paired-end reads were obtained per 492 
sample. DESeq (version 3.0.2) was used to calculate reads per kilobase per million (RPKM). All 493 
genes from placenta were grouped into four classes according to their RPKM values (0–1, 1–10, 494 
10–100, and >100). Genes with moderate to high expression were defined by >10 mapped reads 495 
per RPKM and treated as placenta expressed genes.  496 
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  497 
Protein-coding genes from de novo CNV regions were extracted from the UCSC browser 498 
(https://genome.ucsc.edu/). Human genome build GRC37/hg19 was used as a reference. Genes 499 
found at de novo CNV regions were studied for gene expression in placental tissue from 12 500 
individuals. Enrichment analyses for Gene Ontology terms were performed for genes present at 501 
de novo CNVs, by using g:Profiler (version Ensembl 90, Ensembl Genomes 37, rev 1741, build 502 
date 2017-10-19)47 with default settings. Briefly, this tool performs gene set enrichment analyses 503 
for Gene Ontology, Human Phenotype Ontology and Kyoto Encyclopedia of Gene and Genomes 504 
gene sets. Enrichment analyses are conducted by hypergeometric test and resulting enrichment 505 
P-values are further adjusted for multiple testing by g:SCS (Set Counts and Sizes) method, 506 
developed to address the non-independent structure of tested GO terms47. Separate enrichment 507 
analyses were conducted to different groups of genes, based on cohort, CNV type and expression 508 
in placenta (all genes and placenta expressed genes). Results were filtered hierarchically, and 509 
only the most significant ontology per parent group was shown. De novo CNVs with gains and 510 
losses were analyzed separately. 511 
 512 
Validation by ddPCR. We applied ddPCR to validate low-level mosaic aberrations (Fig. 2c and 513 
Supplementary Table 3). We used a proof-of-principle assay to evaluate the sensitivity of 514 
TaqMan-based ddPCR. A DNA sample from a trisomy 21 (copy number, CN = 3) cell line was 515 
mixed with a DNA sample from a normal diploid cell line (CN = 2) at different ratios, creating 516 
admixture series of DNA samples with 100%, 75%, 50%, 25%, 10–15% and 0% abnormal 517 
alleles (Extended Data Fig. 6). The cell lines of EBV-immortalized lymphocytes had been 518 
established in-house using blood samples from patients of Centre for Human Genetics, UZ 519 
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Leuven, Leuven, Belgium, and were authenticated by conventional karyotyping. Mycoplasma 520 
PCR was performed to ensure that the cell lines are not contaminated48. To evaluate the level of 521 
Chr 21 mosaic gain, the FAM-fluorescent TaqMan copy number assay probe for the RUNX1 522 
gene locus (dHsaCP1000308) was used as a target probe. The HEX-fluorescent TaqMan copy 523 
number reference assay AP3B1 probe (dHsaCP2500348) was used as an internal reference 524 
control (Bio-Rad, Hercules, CA).  525 
The ddPCR system was operated according to the manufacturer’s instructions. Briefly, 526 
before droplet generation, restriction enzyme HaeIII (New England Biolabs Inc.) was added 527 
directly to the ddPCR reaction mixture and incubated for 20 min at room temperature. 528 
Subsequently, droplets were generated in a DG8 disposable droplet generator cartridge using a 529 
QX100 Droplet Generator (Bio-Rad). PCR amplification was performed by using the following 530 
conditions: 95 °C for 10 min, followed by 40 cycles of 94 °C for 30 s and 59 °C for 1 min and, 531 
finally, 98 °C for 10 min. Droplets were counted by using the QX100 Droplet Reader. Data were 532 
analyzed by using QuantaSoft Software (Bio-Rad).  533 
Mosaic ratio was calculated based on the total positive signal counts of RUNX1 534 
normalized against reference AP3B1 positive signal counts. All analyzed samples were run in 535 
four-replicate reactions. Mosaic placental DNA samples were processed in the same manner by 536 
performing initial DNA digestion, followed by droplet generation and PCR amplification. All 537 
DNA samples were quantified by using the TaqMan copy number assay target probes for the 538 
specific gene in the region of interest. The AP3B1 probe was used as an internal reference 539 
control (Supplementary Table 3). 540 
 541 
Code availability. Custom code is available upon request. 542 
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 543 
Data availability. All SNP array data generated in this study were deposited in the 544 
NCBI Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/) under accession 545 
number GEO: GSE93353. 546 
 547 
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